This article is more than 5 years old. Information may no longer be current.
Oyster Point announces positive results with dry eye drugs
Click Here to Manage Email Alerts
Oyster Point Pharma announced that studies of its novel therapies for treating dry eye demonstrated improvement in Schirmer’s score and multiple measures of eye dryness symptoms.
The ONSET and RAINIER studies were phase 2b clinical trials, the company said in a press release.
“The results announced today demonstrate the potential clinical benefits of the innovative therapeutics Oyster Point Pharma is developing,” Edward Holland, MD, professor of ophthalmology, University of Cincinnati, and member of Oyster Point Pharma’s medical advisory board, said in the release. “There is a significant need for a novel treatment approach for dry eye disease. A therapeutic that can help patients to produce their own natural tear film has the potential to benefit a broad population of patients with dry eye disease.”
The ONSET study was a dose-ranging, randomized, double-masked, vehicle-controlled phase 2b clinical trial that evaluated the safety and efficacy of OC-01 in 182 subjects with dry eye disease in the U.S. The study compared three different doses of OC-01 nasal spray to vehicle control nasal spray
The RAINIER study was a randomized, double-masked, vehicle-controlled, phase 2b clinical trial that evaluated the safety and efficacy of 2.0% OC-02 nasal spray in 53 subjects (2:1 randomization) with dry eye in the U.S.
Results showed a statistically significant improvement in Schirmer’s score at day 28 in all three doses compared to control. Results demonstrated an increase in tear film production as measured by an improvement in Schirmer’s score in the study eye at day 28 compared to vehicle control.